Evidence map›Paper›PMID 33854623›Full record

ArticleJournal of Cancer2021

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China.

Zhongqing Zou, Tingting Guo, Jian Cui, Wenjiao Tang, Yan Li, Fangfang Wang, Tian Dong, Yunfan Yang, Yan Feng, Matthew Ho and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Zhongqing ZouDepartment of Hematology, West China Hospital, Sichuan University, China.
Tingting GuoDepartment of Hematology, West China Hospital, Sichuan University, China.
Jian CuiDepartment of Hematology, West China Hospital, Sichuan University, China.
Wenjiao TangDepartment of Hematology, West China Hospital, Sichuan University, China.
Yan LiDepartment of Hematology, West China Hospital, Sichuan University, China.
Fangfang WangDepartment of Hematology, West China Hospital, Sichuan University, China.
Tian DongDepartment of Hematology, West China Hospital, Sichuan University, China.
Yunfan YangDepartment of Hematology, West China Hospital, Sichuan University, China.
Yan FengDepartment of Hematology, West China Hospital, Sichuan University, China.
Matthew HoDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, United States.
Li ZhangDepartment of Hematology, West China Hospital, Sichuan University, China.
Ling PanDepartment of Hematology, West China Hospital, Sichuan University, China.
Ting NiuDepartment of Hematology, West China Hospital, Sichuan University, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) is a heterogeneous disease that remains incurable with significant interpatient variability in outcomes. Regulatory B cells (Bregs) were observed to be involved into specific defects in MM. Here, we provide our risk-adapted approach to newly diagnosed MM (NDMM), combining with the fundamental dysfunction of Bregs. We reported one hundred consecutive patients with NDMM from South-Western China, primarily treated with bortezomib plus dexamethasone with or without a 3

Indexed as

B cellbortezomibmyelomaprognosisreal world

Identifiers

PMID33854623
PMCPMC8040702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.